Copyright and Disclaimer Print


AR 66/2007 SCHEDULED DRUGS REGULATION

(Consolidated up to 11/2017)

ALBERTA REGULATION 66/2007

Pharmacy and Drug Act

SCHEDULED DRUGS REGULATION

Table of Contents

                1      Schedule 1 drugs

                2      Schedule 2 drugs

                3      Schedule 3 drugs


                4      Repeal

                6      Coming into force

Schedule 1 drugs

1(1)   Subject to subsection (2), the following drugs are designated as Schedule 1 drugs for the purposes of section 31(1)(c) of the Pharmacy and Drug Act:

                               (a)    drugs set out in Schedule I of the National Association of Pharmacy Regulatory Authorities Drug Schedules (as amended or replaced from time to time) published by the National Association of Pharmacy Regulatory Authorities, other than drugs described in section 31(1)(a) or (b) of the Act;

                              (b)    vaccines for diphtheria, tetanus, pertussis, polio, haemophilus B, measles, meningitis, mumps, rubella and pediatric hepatitis B.

(2)  Repealed AR 11/2017 s2.

AR 66/2007 s1;61/2016;11/2017

Schedule 2 drugs

2(1)  Subject to subsection (2), the following drugs are designated as Schedule 2 drugs for the purposes of section 32(1)(a) of the Pharmacy and Drug Act:

                               (a)    the drugs set out in Schedule II of the National Association of Pharmacy Regulatory Authorities Drug Schedules (as amended or replaced from time to time) published by the National Association of Pharmacy Regulatory Authorities;

                              (b)    iodinated casein;

                           (b.1)    repealed AR 11/2017 s3;

                               (c)    repealed AR 34/2012 s2.

(2)  The following drugs are excluded from the designation under subsection (1)(a):

                               (a)    vaccines for diphtheria, tetanus, pertussis, polio, haemophilus B, measles, meningitis, mumps, rubella and pediatric hepatitis B;

                              (b)    diphenhydramine and its salts for topical use;

                               (c)    charcoal (activated) for use in poisoning treatment;

                              (d)    hydroquinone (topical preparations in concentrations of less than 2%);

                               (e)    naloxone and its salts, when indicated for emergency use for opioid overdose outside hospital settings.

AR 66/2007 s2;34/2012;61/2016;11/2017

Schedule 3 drugs

3(1)  Subject to subsection (2), the following drugs are designated as Schedule 3 drugs for the purposes of section 33(1) of the Pharmacy and Drug Act:

                               (a)    the drugs set out in Schedule III of the National Association of Pharmacy Regulatory Authorities Drug Schedules (as amended or replaced from time to time) published by the National Association of Pharmacy Regulatory Authorities;

                              (b)    drugs for veterinary use that are to be administered by injection.

(2)  The following drugs are excluded from the designation under subsection (1):

                               (a)    acetaminophen (in sustained release formulations);

                              (b)    acetylsalicylic acid and its salts (in products for oral, adult use, in strengths of 81 mg/dosage unit and 650 mg or greater/dosage unit and in rectal preparations containing more than 150 mg/dosage unit);

                               (c)    aloe vera latex, its extracts and derivatives (except aloin) (dosage forms for systemic use containing more than 300 mg/dosage unit);

                              (d)    aluminum oxide;

                               (e)    anetholtrithione;

                               (f)    antazoline and its salts;

                               (g)    antipyrine (for otic use);

                              (h)    benzonatate;

                               (i)    berberis vulgaris (barberry);

                               (j)    brompheniramine and its salts;

                              (k)    calcium polycarbophil;

                               (l)    carbinoxamine and its salts;

                             (m)    casanthranol;

                              (n)    cerapon;

                              (o)    chlophendianol and its salts;

                              (p)    chlorzoxazone and its salts;

                              (q)    clemastine and its salts;

                               (r)    danthron;

                               (s)    dehydrocholic acid and its salts;

                               (t)    deoxycholic acid and its salts;

                              (u)    dexbrompheniramine and its salts;

                              (v)    dextromethorphan and its salts;

                              (w)    repealed AR 34/2012 s2;

                              (x)    dimethothiazine;

                              (y)    diphenhydramine and its salts and preparations;

                               (z)    diphenylpyraline;

                             (aa)    doxylamine and its salts (except those sold for nausea and vomiting related to pregnancy);

                            (bb)    electrolyte solutions for oral hydration;

                             (cc)    fractar;

                            (dd)    glyceroargentinate;

                             (ee)    haloprogin;

                              (ff)    iodine and its salts and derivatives (for topical use);

                             (gg)    lactic acid;

                            (hh)    lactulose;

                              (ii)    loratadine and its salts and preparations;

                              (jj)    magnesium citrate (cathartics);

                            (kk)    magnesium salicylate (except oral dosage forms which also contain choline salicylate);

                              (ll)    narcotine and its salts (Noscapine);

                          (mm)    oxethazine;

                            (nn)    phenyltoloxamine and its salts;

                            (oo)    povidone‑iodine (vaginal and topical preparations);

                            (pp)    promethazine and its salts (for topical use);

                            (qq)    ephedrine and its salts in combination products (for use in treatment of nasal congestion, in strengths of no more that 8 mg/dosage unit and with a label recommending a maximum treatment of 7 days of not more than 8 mg/dose and 32 mg/day);

                              (rr)    pseudoephedrine and its salts and preparations in combination products;

                             (ss)    sodium biphosphate (cathartics);

                              (tt)    sodium phosphate (cathartics);

                            (uu)    triethanolamine oleate;

                            (vv)    triethanolamine salicylate (in concentrations greater than 20%);

                           (ww)    tripelennamine and its salts;

                            (xx)    triprolidine;

                            (yy)    tyrothricine.

AR 66/2007 s3;34/2012

Repeal

4   The Scheduled Drugs Regulation (AR 86/2002) is repealed on the coming into force of section 34 of the Pharmacy and Drug Act.

5   Repealed AR 109/2016 s2.

Coming into force

6   This Regulation comes into force on the coming into force of section 34 of the Pharmacy and Drug Act.